{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63","upperLimit":"83","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"Estimate for probability of progression free survival by Kaplan-Meier method, where progression-free survival is defined as the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. PFS is censored in patients who are alive and have not progressed. Progression is assessed by RECIST 1.1","dispersionType":"90% Confidence Interval","groups":[{"description":"Gemcitabine 50 mg/m2 and Cisplatin 40mg/m2 administered weekly throughout IMRT radiation therapy. Gemcitabine will be infused prior to cisplatin and given over approximately 30 minutes while the cisplatin will be delivered over approximately 60 minutes.","id":"OG000","title":"GEM+CIS+IMRT"}],"paramType":"NUMBER","populationDescription":"Eligible and treated","reportingStatus":"POSTED","timeFrame":"From study entry to disease progression, death or date of last contact, whichever occurs first. The median for observed PFS was 26.2 month with a range from 1.5 months to 82.4 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}